Flaws in a tumor’s genetic mending kit drive treatment response to immunotherapy

Via Top Health News -- ScienceDaily

In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called 'mismatch repair' genetic defects, scientists have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda).

View original post here:

%d bloggers like this: